Skip Nav Destination
![]()
You do not currently have access to this content.
ADC for Lymphoma Elicits Near-Perfect Response Rate
December 30, 2024
In a phase II trial, the ROR1-targeting antibody–drug conjugate zilovertamab vedotin led to a complete response in nearly 100% of patients with diffuse large B-cell lymphoma.
RSS Feeds